Dynamics of Antibiotic Resistance of
PCV impact
acute otitis media
children
next-generation pneumococcal conjugate vaccine
pneumococcal nasopharyngeal carriage
third-generation pneumococcal conjugate vaccine
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
28
04
2023
revised:
23
05
2023
accepted:
31
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Epidemiological surveillance of nasopharyngeal pneumococcal carriage is important for monitoring serotype distribution and antibiotic resistance, particularly before and after the implementation of pneumococcal conjugate vaccines (PCVs). With a prospective surveillance study in France, we aimed to analyze the dynamics of pneumococcal carriage, antibiotic susceptibility and serotype distribution in children aged 6 to 24 months who had acute otitis media between 2001 and 2022 with a focus on the late PCV13 period from May 2014 to July 2022. Trends were analyzed with segmented linear regression with autoregressive error. For the 17,136 children enrolled, overall pneumococcal carriage was stable during the study. During the late PCV13 period, the five most frequent serotypes were all non-PCV13 serotypes: 15B/C (14.3%), 23B (11.0%), 11A (9.6%), 15A (7.4%) and 35B (6.5%). During the same period, we observed a rebound of penicillin non-susceptibility (+0.15% per month, 95% confidence interval, +0.08 to 0.22,
Identifiants
pubmed: 37370339
pii: antibiotics12061020
doi: 10.3390/antibiotics12061020
pmc: PMC10295685
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer (France)
ID : NA
Références
J Infect Dis. 1997 Jun;175(6):1440-5
pubmed: 9180184
Lancet Infect Dis. 2004 Mar;4(3):144-54
pubmed: 14998500
Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78
pubmed: 29227464
Pediatr Infect Dis J. 2012 Mar;31(3):297-301
pubmed: 22330166
Lancet Infect Dis. 2021 Jan;21(1):137-147
pubmed: 32702302
Vaccine. 2015 Sep 22;33(39):5118-26
pubmed: 26271823
Hum Vaccin Immunother. 2016;12(2):268-76
pubmed: 26430921
Hum Vaccin Immunother. 2016;12(2):277-84
pubmed: 26905678
J Pediatr. 2018 Mar;194:269-270.e2
pubmed: 29637893
J Antimicrob Chemother. 2022 Mar 31;77(4):1045-1051
pubmed: 35045160
Vaccine. 2021 Jan 8;39(2):372-379
pubmed: 33308889
BMC Infect Dis. 2013 Oct 10;13:474
pubmed: 24112237
J Antimicrob Chemother. 2020 Aug 1;75(8):2344-2352
pubmed: 32449915
Clin Infect Dis. 2005 May 1;40(9):1223-6
pubmed: 15825021
J Clin Epidemiol. 2015 Aug;68(8):950-6
pubmed: 25890805
Clin Infect Dis. 2021 Apr 26;72(8):1453-1456
pubmed: 32804200
Infect Immun. 2003 Nov;71(11):6192-8
pubmed: 14573636
Clin Infect Dis. 2022 Aug 24;75(1):e1154-e1164
pubmed: 34904635
Clin Infect Dis. 2008 Feb 15;46(4):e34-7
pubmed: 18205533
Lancet Reg Health Am. 2023 Feb 15;19:100448
pubmed: 36852331
J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086
pubmed: 31280295
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347199
Lancet Microbe. 2022 Oct;3(10):e735-e743
pubmed: 35985351
Lancet Digit Health. 2021 Jun;3(6):e360-e370
pubmed: 34045002
Expert Rev Vaccines. 2012 Jul;11(7):841-55
pubmed: 22913260
China CDC Wkly. 2022 Dec 9;4(49):1097-1100
pubmed: 36751661
Pediatrics. 2017 Sep;140(3):
pubmed: 28784702
Clin Exp Vaccine Res. 2021 May;10(2):81-92
pubmed: 34222121
Lancet Microbe. 2022 Oct;3(10):e744-e752
pubmed: 35932764
Lancet Infect Dis. 2021 Jan;21(1):14-16
pubmed: 32702301
BMC Infect Dis. 2022 Mar 26;22(1):294
pubmed: 35346092
Pediatr Infect Dis J. 2017 Mar;36(3):245-249
pubmed: 27870813
J Pediatr. 1987 Dec;111(6 Pt 1):948-51
pubmed: 3681566
Curr Infect Dis Rep. 2006 May;8(3):189-95
pubmed: 16643770
Am J Epidemiol. 2013 Nov 1;178(9):1488-95
pubmed: 24013204
JAMA Netw Open. 2022 Jun 1;5(6):e2218959
pubmed: 35763298
Paediatr Drugs. 2008;10(2):75-83
pubmed: 18345717